Prevalence of Mood and Anxiety Disorders in Adult Patients With Pulmonary Langerhans Cell Histiocytosis
NCT ID: NCT05114304
Last Updated: 2021-11-09
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
100 participants
OBSERVATIONAL
2021-11-30
2022-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This study should allow:
* to assess the prevalence of psychiatric disorders co-morbid in PLCH patients
* a targeted and more effective management of patients
* a better response rate to smoking and cannabis weaning, that represents a major goal for these patients.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Pulmonary Langerhans cell histiocytosis (PLCH)
Adults with pulmonary Langerhans cell histiocytosis
Evaluation of co-morbid psychiatric disorders
Added scales :
* Mini Internationnal Neuropsychiatric Interview
* Fagerström test
* DSM-5 Scale
Additional dosage : - a urine sample will be taken to evaluate the presence of tobacco and nicotine breakdown products and the presence of various toxics
Expired carbon monoxide for patients using nicotine substitutes
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Evaluation of co-morbid psychiatric disorders
Added scales :
* Mini Internationnal Neuropsychiatric Interview
* Fagerström test
* DSM-5 Scale
Additional dosage : - a urine sample will be taken to evaluate the presence of tobacco and nicotine breakdown products and the presence of various toxics
Expired carbon monoxide for patients using nicotine substitutes
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients affiliated to the French Health Care System
* Informed patients
Exclusion Criteria
* Patient under guardianship or curatorship
* Patient under AME (French medical help for foreigners)
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Assistance Publique - Hôpitaux de Paris
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hôpital Saint-Louis, Centre de référence national des histiocytoses, Service de Pneumologie
Paris, , France
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Abdellatif TAZI
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
APHP210292
Identifier Type: -
Identifier Source: org_study_id